[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vigonvita Life Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":189},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,66,84,105,124,150,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100579791","phase-2-dose-finding-clinical-trial-to-evaluate-the-efficacy-and-safety-of-lv232-capsules-in-the-treatment-of-mdd-100579791",false,"NCT06828887","Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD","Multicenter,Randomized,Double-blind,Placebo,Parallel-controlled,Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of Major Depressive Disorder (MDD)","Inclusion Criteria:\n\n1. Fully understand the purpose, content, and potential adverse reactions of this trial, voluntarily participate in the clinical trial and sign a written informed consent form, able to complete the entire trial process as required and comply with the trial regulations;\n2. Gender unrestricted, at screening: 18 years old ≤ age ≤ 65 years old;\n3. Meet the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) diagnostic criteria for depression according to the Mini International Neuropsychiatric Interview (M.I.N.I. 7.0.2), currently experiencing a single or multiple episodes;\n4. For first-episode patients, the duration of the current depressive episode must be ≥3 months; for recurrent patients, the duration of the current depressive episode must be ≥1 month (each month is counted as 30 days, the same applies below);\n5. During the screening and baseline periods, the total score on the Montgomery-Asberg Depression Rating Scale (MADRS) must be ≥26, and the Clinical Global Impression-Severity (CGI-S) score must be ≥4;\n6. At screening and baseline visits, the score on the first item (depressed mood) of the HAMD-17 scale must be ≥2;\n7. Female or male subjects of childbearing potential agree and commit to using effective contraception from the signing of the informed consent form until 3 months after the last administration of the trial drug.\n\nExclusion Criteria:\n\n1. Treatment-resistant depression (failure to respond to an adequate dose and duration of treatment, at least 8 weeks, with two antidepressants of different mechanisms) or failure to respond to an adequate dose and duration of treatment with escitalopram oxalate;\n2. Meeting the diagnostic criteria for other mental disorders as per DSM-5 (such as schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, generalized anxiety disorder, obsessive-compulsive and related disorders, somatic symptom and related disorders, etc.);\n3. Meeting the DSM-5 criteria for substance use disorder;\n4. Organic mental disorders, such as depression caused by hypothyroidism;\n5. Depression induced by psychoactive substances or non-addictive substances;\n6. Presence of depressive symptoms due to other diseases or other types of mental disorders;\n7. A reduction of ≥25% in the MADRS score at baseline compared to the screening period;\n8. Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) and judged by the investigator to be at risk of suicide, or having suicidal behavior within the 6 months prior to screening;\n9. Presence of severe physical illnesses deemed by the investigator as grounds for exclusion, such as uncontrolled hypertension or severe unstable cardiovascular diseases, severe liver diseases, kidney diseases, blood diseases, endocrine diseases, neurological diseases, etc.;\n10. Diseases affecting oral drug absorption, such as active bowel disease, partial or complete intestinal obstruction, chronic diarrhea, etc.;\n11. Active malignancy or a history of malignancy within 5 years prior to screening (except for completely resected and cured squamous cell carcinoma, cervical carcinoma in situ, etc.);\n12. History of increased intraocular pressure or narrow-angle glaucoma;\n13. Individuals with allergic constitution, such as those allergic to two or more drugs or known to be allergic to escitalopram oxalate;\n14. Use of drugs that alter the activity of liver enzymes (CYP2C19 and CYP2D6) within 4 weeks (or 5 half-lives, whichever is longer) prior to randomization (see Appendix 2);\n15. Previous treatment with vagus nerve stimulation (VNS) and deep brain stimulation (DBS), or modified electroconvulsive therapy (MECT) within 3 months prior to randomization, or systematic psychotherapy (interpersonal therapy, dynamic therapy, cognitive behavioral therapy), transcranial magnetic stimulation (TMS), and light therapy within 1 month prior to randomization, or judged by the investigator to currently require such treatments;\n16. Systematic antidepressant treatment within 2 weeks prior to randomization (not less than 30 days for fluoxetine), or discontinuation of psychotropic drugs for less than 5 half-lives prior to randomization (except for stable doses of sleep aids received within 4 weeks prior to randomization, including benzodiazepines (limited to estazolam, alprazolam, and oxazepam) and non-benzodiazepines);\n17. Use of monoamine oxidase inhibitors such as phenelzine, isocarboxazid, tranylcypromine, etc., and linezolid, methylene blue, etc., within 2 weeks prior to randomization;\n18. Second or third-degree atrioventricular block, long QT syndrome, or QTcF \\> 450 ms (male)\u002F460 ms (female) on 12-lead ECG at screening;\n19. Discontinuation of drugs that prolong the QT interval (such as levofloxacin, fluconazole, ondansetron, amiodarone, metronidazole, erythromycin, and haloperidol, etc.) or drugs that may cause QT interval prolongation and induce torsade de pointes (TdP) for less than 5 half-lives at randomization;\n20. ALT or AST above 2 times the upper limit of normal; creatinine above 1.5 times the upper limit of normal; 2 or more abnormal indicators in thyroid function tests (TSH, FT3, FT4, TT3, or TT4 below 0.9 times the lower limit of normal or above 1.1 times the upper limit of normal) at screening;\n21. Positive for Treponema pallidum antibody and HIV antibody at screening;\n22. Substance abuse (including alcohol, drugs, and other psychoactive substances) within 3 months prior to screening;\n23. Female subjects who are breastfeeding or have a positive pregnancy test at screening or during the trial;\n24. Participation in any interventional clinical trial and use of investigational drugs or medical devices within 3 months prior to screening, or currently participating in other clinical trials;\n25. Other factors deemed by the investigator as unsuitable for participation in the trial.","ALL","18 Years","65 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding Phase II clinical trial aimed to determine the optimal dose of LV232 capsules for treating MDD, evaluate preliminary efficacy and safety, and provide a basis for Phase III trial design and dosing regimen determination.",[27],"MDD","RECRUITING","2026-05-18",{"date":31,"type":32},"2026-05-20","ACTUAL",{"date":34,"type":32},"2025-04-03",{"date":36,"type":21},"2026-12-20",{"name":38,"class":39},"Vigonvita Life Sciences","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":48,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100636446","phase-1-study-of-food-effects-of-vv913-capsules-in-chinese-healthy-volunteers-100636446","NCT07565792","Study of Food Effects of VV913 Capsules in Chinese Healthy Volunteers","Inclusion Criteria:\n\n1. Aged 18 to 45 years old, males ;\n2. Males weight no less than 50 kg, with body mass index of 19 to 26 kg\u002Fm\\^2;\n3. Vital signs examination, physical examination, laboratory examination ,Chest X-ray are normal or considered abnormal without clinical significance by the investigator;\n4. Participants who are willing to take proper contraceptive methods during the study and within 3 months after the the last administration;\n5. Participants who are able to understand and follow the study protocol and instructions; participants who have voluntarily decided to participate in this study, and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Participants with hypersensitivity to preparation or any of the excipients;\n2. Participants with allergic constitution (such as asthma, urticaria, eczematous dermatitis and other allergic diseases), or have a history of drug or food allergy;\n3. Participants with central nervous system, cardiovascular system, gastrointestinal, respiratory system, urinary, hematologic, or metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials; Participants with a history of gastrointestinal conditions that may impair drug absorption (e.g., gastrectomy or small intestine resection, atrophic gastritis, gastrointestinal ulcers or perforations\u002Ffistulas, gastrointestinal bleeding, or obstruction);\n4. Participants with a history of surgery within 3 months before screening, or have not recovered from surgery, or have an expected surgical plan during the trial;\n5. Participants with a blood donation or blood loss ≥ 400 mL within 3 months before screening, or a history of blood product use within 3 months before screening;\n6. Participating in any clinical trial and taking clinical trial drugs within 90 days before screening;\n7. Participants who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before screening;\n8. Participants who have received vaccination within 14 days before screening, or planned to receive any vaccine during the trial or within 1 week after the end of the study;\n9. Participants with a history of drug abuse within 1 year before screening or positive urine drug screening within 1 year before screening results (morphine, tetrahydrocannabinol, methamphetamine, dimethylene diphenazine , ketamine, and cocaine);\n10. Participants who drink more than 14 standard units or at least twice a day per week within one year before screening (one standard unit equals 200 mL of beer with 5% alcohol or 25 mL of spirits with 40% alcohol content or 85 mL of wine with 12% alcohol content);\n11. Participants who smoke more than 5 cigarettes a day within one year before screening;\n12. Participants who can't quit smoking or drinking during the trial period;\n13. Participants who are positive for hepatitis B virus surface antigen, hepatitis C virus antibody, treponema pallidum antibody or human immunodeficiency virus antibody (Anti-HIV）;\n14. Having special requirements for food, unable to observe a unified diet or having dysphagia;\n15. Participants who cannot avoid consuming drinks containing xanthine (such as coffee and tea) or foods (such as chocolate and animal liver), or fruits or juices (such as grapefruit, pomelo, mango, and dragon fruit) that may affect drug metabolism，from 48 hours before administration until the end of the study;\n16. Participants who cannot tolerate blood collection with intravenous indwelling needles or blood fainting;\n17. Participants with difficulty in swallowing capsules;\n18. Participants whose female partners plan to conceive within 3 months;\n19. The investigator believes that there are other unsuitable factors to participate this trial.",true,"MALE","45 Years",{"count":51,"type":21},12,[53],"PHASE1","This study is a single-center, randomized, open label, 3×3 crossover design to assess the high-fat meal and the standard meal effects on PK of a single oral dose of VV913 in healthy adult volunteers.",[56],"Healthy Volunteers","NOT_YET_RECRUITING","2026-04-27",{"date":60,"type":32},"2026-05-04",{"date":62,"type":21},"2026-05-15",{"date":64,"type":21},"2026-12-31",{"name":38,"class":39},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":47,"sex":48,"minAge":17,"maxAge":49,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":40},"100621598","phase-1-study-of-the-safety-tolerability-pharmacokinetics-of-vv913-capsules-in-chinese-healthy-participants-100621598","NCT07372703","Study of the Safety, Tolerability, Pharmacokinetics of VV913 Capsules in Chinese Healthy Participants","A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of a Single Oral Dose of VV913 Capsules in Chinese Healthy Participants","Inclusion Criteria:\n\n1. Aged 18 to 45 years old, males ;\n2. Males weight no less than 50 kg, with body mass index of 19 to 26 kg\u002Fm\\^2;\n3. Vital signs examination, physical examination, laboratory examination ,electrocardiogram examination chest CT are normal or considered abnormal without clinical significance by the investigator;\n4. Participants who are willing to take proper contraceptive methods during the study and within 3 months after the the last administration;\n5. Participants who are able to understand and follow the study protocol and instructions; participants who have voluntarily decided to participate in this study, and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Participants with hypersensitivity to preparation or any of the excipients;\n2. Participants with allergic constitution (such as asthma, urticaria, eczematous dermatitis and other allergic diseases), or have a history of drug or food allergy;\n3. Participants with central nervous system, cardiovascular system, gastrointestinal, respiratory system, urinary, hematologic, or metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials; Participants with a history of gastrointestinal conditions that may impair drug absorption (e.g., gastrectomy or small intestine resection, atrophic gastritis, gastrointestinal ulcers or perforations\u002Ffistulas, gastrointestinal bleeding, or obstruction);\n4. Participants with a history of surgery within 3 months before screening, or have not recovered from surgery, or have an expected surgical plan during the trial;\n5. Participants with a blood donation or blood loss ≥ 400 mL within 3 months before screening, or a history of blood product use within 3 months before screening;\n6. Participating in any clinical trial and taking clinical trial drugs within 90 days before screening;\n7. Participants who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before screening;\n8. Participants who have received vaccination within 14 days before screening, or planned to receive any vaccine during the trial or within 1 week after the end of the study;\n9. Participants with a history of drug abuse within 1 year before screening or positive urine drug screening within 1 year before screening results (morphine, tetrahydrocannabinol, methamphetamine, dimethylene diphenazine , ketamine, and cocaine);\n10. Participants who drink more than 14 standard units or at least twice a day per week within one year before screening (one standard unit equals 200 mL of beer with 5% alcohol or 25 mL of spirits with 40% alcohol content or 85 mL of wine with 12% alcohol content);\n11. Participants who smoke more than 5 cigarettes a day within one year before screening;\n12. Participants who can't quit smoking or drinking during the trial period;\n13. Participants who are positive for hepatitis B virus surface antigen, hepatitis C virus antibody, treponema pallidum antibody or human immunodeficiency virus antibody (Anti-HIV）;\n14. Having special requirements for food, unable to observe a unified diet or having dysphagia;\n15. Participants who cannot avoid consuming drinks containing xanthine (such as coffee and tea) or foods (such as chocolate and animal liver), or fruits or juices (such as grapefruit, pomelo, mango, and dragon fruit) that may affect drug metabolism，from 48 hours before administration until the end of the study;\n16. Participants who cannot tolerate blood collection with intravenous indwelling needles or blood fainting;\n17. Participants with difficulty in swallowing capsules;\n18. Participants whose female partners plan to conceive within 3 months;\n19. The investigator believes that there are other unsuitable factors to participate this trial.",{"count":74,"type":21},56,[53],"This is a randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics characteristics of VV913 Capsules in healthy adults.",[56],{"date":60,"type":32},{"date":80,"type":32},"2026-01-29",{"date":82,"type":21},"2026-10",{"name":38,"class":39},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},"100554838","phase-1-evaluating-safety-tolerability-and-pharmacokinetic-of-multiple-ascending-doses-of-vv119-100554838","NCT06504290","Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119","A Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VV119 Capsules With Multiple Ascending Doses in Chinese Healthy Adult Subjects and Patients With Schizophrenia","Inclusion Criteria:\n\nHealthy adult subjects：\n\n1. Males: aged 18 to 45 years old, Body weight no less than 50.0kg; females: Aged 18 to 60 years old, Body weight no less than 45.0kg, Body Mass Index of 19.0 to 26.0kg\u002Fm2.\n2. Medically healthy, physical examination, vital signs examination, laboratory examination, electrocardiogram examination results were normal or abnormal without clinical significance.\n3. Males' subjects who are willing to take effective contraceptive during the study and within 6 months after the study completed; females of non-child-bearing potential.\n4. Subjects who are able to understand and follow study plans and instructions; Subjects who have voluntarily decided to participate in this study and signed the informed consent form.\n\nAdult patients with schizophrenia:\n\n1. Aged 18 to 65 years old, Body Mass Index of 18.5 to 30kg\u002Fm2, males, Body weight no less than 50.0kg; females: Body weight no less than 45.0kg.\n2. Males' subjects who are willing to take effective contraceptive during the study and within 6 months after the study completed; females of non-child-bearing potential.\n3. Subject has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the DSM-5 and MINI at least 1 year.\n4. Subject is experiencing an acute exacerbation or relapse of psychotic symptoms.\n5. PANSS total score at least 70 and CGI-S score of ≥4 at screening.\n6. Subjects who have a history of antipsychotics.\n7. The subjects and their guardians fully understand the purpose and requirements of the trial, voluntarily participate in the clinical trial and sign the written informed consent form and are willing to complete the whole trial process according to the trial requirements.\n\nExclusion Criteria:\n\nHealthy adult subjects：\n\n1. With current or past medical history diseases or dysfunction that affect the clinical trial, evaluated by the investigator, including but not limited to central nervous system, cardiovascular system, respiratory system, digestive system, urinary system, endocrine system, blood system, ophthalmology and other diseases, history of malignant tumor or other diseases that are not suitable for participating in the clinical trial.\n2. With current or previous mental disorders and brain dysfunction, or suicide risk according to the clinical judgment of the investigator, or a history of self-mutilation.\n3. With any surgical condition or condition that may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects participating in the trial, such as history of gastrointestinal surgery (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction or dysuria, gastroenteritis, gastrointestinal ulcers, history of gastrointestinal bleeding, etc.\n4. With a known history of allergy to investigating drug ingredients or similar drugs, a history of allergic diseases or allergic constitution.\n5. Positive for hepatitis B virus surface antigen （HBsAg）, or syphilis antibody (Anti-TP), or hepatitis C antibody (anti-HCV), or human immunodeficiency virus antigen\u002Fantibody combined detection (HIV-Ag\u002FAb).\n6. With a history of surgery within 3 months before screening, or have not recovered from surgery, or have an expected surgical plan during the trial.\n7. With a blood donation or blood loss ≥ 400mL within 3 months before screening, or a blood donation or blood loss ≥ 200mL within 1 month, or a history of blood product use within 3 months before screening.\n8. Taking any prescription drugs, over-the-counter drugs, and any functional vitamins or herbal products within 2 weeks before screening.\n9. Using any drugs that inhibit or induce hepatic drug metabolizing enzymes CYP3A4, CYP3A5, CYP2D6 (such as inducers - phenobarbital, rifampicin, carbamazepine, phenytoin sodium, glucocorticoids, etc.; inhibitors - ketoconazole, itraconazole, cimetidine, clarithromycin, verapamil, erythromycin, etc.) within 4 weeks (or 5 half-lives, whichever is longer) before screening.\n10. Participating in any clinical trial and taking clinical trial drugs within 3 months before screening, or being participating in other clinical trials.\n11. Smoke test positive or smoking more than 5 cigarettes per day or average intake of coffee or tea more than 5 cups per day (200 mL\u002Fcup) within 3 months before screening, or unable to stop users during the study.\n12. With alcohol abuse within 1 year before screening, average weekly alcohol intake more than 14 standard units \\[1 unit = 360 mL beer (alcohol content 5%) or 45 mL spirits (alcohol content 40%) or 150 mL wine (alcohol content 12%)\\] or positive for alcohol breath test.\n13. With a history of drug abuse within 1 year before screening, or positive for urine drug screening.\n14. With a family history of sudden cardiac death (sudden death age less than 40 years).\n15. With a resting pulse \\\u003C 50 beats\u002Fmin or ≥ 100 beats\u002Fmin; resting systolic blood pressure \\\u003C 85 mmHg or ≥ 140 mmHg; resting diastolic blood pressure \\\u003C 50 mmHg or ≥ 90 mmHg; systolic blood pressure decreased by ≥ 20 mmHg and\u002For diastolic blood pressure decreased by ≥ 10 mmHg and\u002For accompanied by clinical symptoms within 3 minutes of standing.\n16. Abnormal in 12-lead electrocardiogram (ECG), clinically significant judged by the investigator (e.g., QTcF\\> 450 ms in men and \\> 470 ms in women).\n17. With the aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine (Cr), urea (Urea), serum prolactin levels beyond the upper limit of normal (ULN)，Neutrophil count below the lower limit of normal (LLN).\n18. Having special requirements for food, unable to observe a unified diet or having dysphagia.\n19. Rejecting abide by the following conditions during the trial: smoking, alcohol or caffeine-containing beverages are prohibited, and strenuous exercise is avoided.\n20. Directly related to this clinical trial.\n21. Other subjects that the investigator considers inappropriate for this trial.\n\nAdult patients with schizophrenia:\n\n1. Patients who meet the DSM-5 diagnostic criteria for other mental diseases.\n2. Patients with refractory schizophrenia to be defined as patients with treatment-resistant schizophrenia who have not achieved clinical improvement after a full course of treatment with at least 2 antipsychotics in the past 5 years.\n3. The answer to question 4 or 5 of the Columbia Suicide Scale (C-SSRS) suicide ideation in the screening period is \"yes\", or the person who has obvious suicide tendency at present or in the past 12 months, or the researcher believes that there is a risk of suicide and violence based on the clinical evaluation of the investigator.\n4. There are diseases or functional disorders that affect the clinical trial, including but not limited to neuropsychiatric, cardiovascular, urinary, digestive, respiratory, muscular, metabolic endocrine, hematology, immunology, skin and tumors, etc., clinically significant chronic diseases or poorly controlled diseases that have an impact on this trial as assessed by the investigator.\n5. With any surgical condition or condition that may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects participating in the trial, such as history of gastrointestinal surgery (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction or dysuria, gastroenteritis, gastrointestinal ulcers, history of gastrointestinal bleeding, etc.\n6. With a history of epilepsy (except for febrile convulsion).\n7. With a history of Malignant syndrome.\n8. With a history of severe allergies.\n9. Received electric shock treatment, and transcranial magnetic stimulation (rTMS) within 3 months before screening;\n10. Subjects are receiving or have recently received (within 5 half-lives, before baseline \\[Day -1\\]) oral antipsychotic medications, antidepressants or mood stabilizers.\n11. CYP3A4 or CYP2D6 potent inhibitors, moderate inhibitors, potent inducers and moderate inducers used within 5 half-lives before enrollment.\n12. Those who have physical examination abnormalities unrelated to schizophrenia at screening, which are judged by the investigator to have an impact on this trial.\n13. With a resting pulse \\\u003C 50 beats\u002Fmin or ≥ 100 beats\u002Fmin; resting systolic blood pressure \\\u003C 85 mmHg or ≥ 140 mmHg; resting diastolic blood pressure \\\u003C 50 mmHg or ≥ 90 mmHg; systolic blood pressure decreased by ≥ 20 mmHg and\u002For diastolic blood pressure decreased by ≥ 10 mmHg and\u002For accompanied by clinical symptoms within 3 minutes of standing.\n14. Abnormal in 12-lead electrocardiogram （ECG）, clinically significant judged by the investigator (e.g., QTcF\\> 450ms in men and \\> 470ms in women).\n15. The laboratory examination during the screening period was abnormal, and the researcher determined that it was of obvious clinical significance, such as: glutamate aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1.5 times the upper limit of the normal value;creatinine (Cr)\\>upper limit of normal value;serum prolactin levels ≥ 5 times the upper limit of the normal value\n16. With a history of drug abuse within 1 year before screening, or positive for urine drug screening.\n17. With alcohol abuse within 1 year before screening, average weekly alcohol intake more than 14 standard units \\[1 unit = 360mL beer (alcohol content 5%) or 45mL spirits （alcohol content 40%） or 150mL wine （alcohol content 12%）\\] or positive for alcohol breath test.\n18. Rejecting abides by the following conditions during the trial: smoking, alcohol or caffeine-containing beverages are prohibited, and strenuous exercise is avoided.\n19. Positive for hepatitis B virus surface antigen （HBsAg）, or syphilis antibody (Anti-TP), or hepatitis C antibody (anti-HCV), or human immunodeficiency virus antigen\u002Fantibody combined detection (HIV-Ag\u002FAb).\n20. With a blood donation or blood loss ≥ 400mL within 3 months before screening, or a blood donation or blood loss ≥ 200mL within 1 month.\n21. Participation in another clinical study within 3 months before screening in which the subject received an experimental or investigational drug agent,or are participating in clinical trials.\n22. Other subjects that the investigator considers inappropriate for this trial.",{"count":92,"type":21},40,[53],"This study will consist of 2 parts: Part Ⅰ-in healthy adult subjects, Part Ⅱ-in adult patients with schizophrenia",[96],"Schizophrenia",{"date":98,"type":32},"2026-04-28",{"date":100,"type":32},"2024-07-16",{"date":102,"type":21},"2026-07-01",{"name":38,"class":39},4,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":48,"minAge":17,"maxAge":49,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":123,"locationsCount":4},"100631988","early-phase-1-safety-and-pharmacokinetics-study-of-multiple-ascending-doses-of-vv913-capsules-100631988","NCT07507838","Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules","Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules in Chinese Healthy Participants",{"count":112,"type":21},24,[114],"EARLY_PHASE1","This study is a single-center, randomized, double-blind, placebo-controlled, dose-escalation trial to assess the safety, tolerability, pharmacokinetics （PK） of multiple doses of VV913 in Chinese healthy adult participants.",[56],"2026-03-27",{"date":119,"type":32},"2026-04-02",{"date":121,"type":21},"2026-04-01",{"date":64,"type":21},{"name":38,"class":39},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":40},"100616181","phase-1-study-of-the-safety-tolerability-pharmacokinetics-of-vv261-tablets-in-chinese-healthy-volunteers-100616181","NCT07302269","Study of the Safety, Tolerability, Pharmacokinetics of VV261 Tablets in Chinese Healthy Volunteers","A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of a Single Oral Dose of VV261 Tablets in Chinese Healthy Volunteers","Inclusion Criteria:\n\n1. Aged 18 to 45 years old, males or females;\n2. Males weight no less than 50 kg, females weight no less than 45 kg, with body mass index of 19 to 26 kg\u002Fm\\^2;\n3. Vital signs examination, physical examination, laboratory examination ,electrocardiogram examination chest CT and B-ultrasound of liver, gallbladder, pancreas, spleen, kidney and thyroid results are normal or considered abnormal without clinical significance by the investigator;\n4. Volunteers who are willing to take proper contraceptive methods during the study and within 3 months after the the last administration;\n5. Volunteers who are able to understand and follow the study protocol and instructions; volunteers who have voluntarily decided to participate in this study, and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Volunteers with hypersensitivity to preparation or any of the excipients;\n2. Volunteers with allergic constitution (such as asthma, urticaria, eczematous dermatitis and other allergic diseases), or have a history of drug or food allergy;\n3. Volunteers with central nervous system, cardiovascular system, gastrointestinal, respiratory system, urinary, hematologic, or metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials;Volunteers with a history of gastrointestinal conditions that may impair drug absorption (e.g., gastrectomy or small intestine resection, atrophic gastritis, gastrointestinal ulcers or perforations\u002Ffistulas, gastrointestinal bleeding, or obstruction);\n4. Volunteers with a history of diseases affecting bone marrow hematopoietic function or reducing immunological function (including leukemia, myelodysplastic syndrome, aplastic anemia, systemic lupus erythematosus, rheumatoid arthritis, etc.) or treatment history (tumor chemotherapy or radiotherapy, use of immunosuppressants, etc.);\n5. Volunteers with a history of spleen diseases;\n6. If any of the following parameters were considered abnormal with clinical significance: white blood cell count, red blood cell count, platelet count, reticulocyte count, and absolute neutrophil count;\n7. If any of the following parameters were considered abnormal with clinical significance: total bilirubin, alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase;\n8. Volunteers who have received blood transfusion or used blood products within 3 months before screening or who have lost more than ≥400 mL of blood due to other reasons (excluding menstruation);\n9. Volunteers who have participated in clinical trials and received drugs within 3 months before screening;\n10. Volunteers who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 2 weeks before screening;\n11. Volunteers who have received vaccination within the first 2 weeks before screening, or planned to receive any vaccine during the trial or within 1 week after the end of the study;\n12. Volunteers with a history of drug abuse within 1 year before screening or positive urine drug screening within 1 year before screening results (morphine, tetrahydrocannabinol, methamphetamine, dimethylene diphenazine , ketamine, and cocaine);\n13. Volunteers who drink more than 14 standard units or at least twice a day per week within one year before screening,(one standard unit equals 200 mL of beer with 5% alcohol or 25 mL of white wine with 40% alcohol content or 85 mL of red wine with 12% alcohol);\n14. Volunteers who smok more than 5 cigarettes a day within one year before screening;\n15. Volunteers who can't quit smoking or drinking during the trial period;\n16. Volunteers who are positive for hepatitis B virus surface antigen, hepatitis C virus antibody, treponema pallidum antibody or human immunodeficiency virus antibody (Anti-HIV);\n17. Volunteers who cannot tolerate blood collection with intravenous indwelling needles or blood fainting;\n18. Volunteers with lactose intolerance or cannot comply with a uniform diet (such as special dietary requirements, intolerance of standard meals, etc.), volunteers who have consumed excessive amounts of strong tea, coffee or caffeinated beverages in the 3 months before screening;\n19. Volunteers with difficulty in swallowing tablets;\n20. Pregnant or lactating women or male volunteers whose female partners plan to conceive within 3 months;\n21. The investigator believes that there are other unsuitable factors to participate this trial.",{"count":132,"type":21},58,[53],"This is a randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics characteristics of VV261 tablets in healthy adults.",[56],[137,138,139,140,141],"VV261","Phase I","Tolerability","Pharmacokinetic","Safety","2026-02-27",{"date":144,"type":32},"2026-03-03",{"date":146,"type":32},"2026-01-04",{"date":148,"type":21},"2026-06-30",{"name":38,"class":39},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":167,"locationsCount":40},"100611442","phase-1-study-of-food-effects-of-vv119-capsules-in-chinese-healthy-volunteers-100611442","NCT07240636","Study of Food Effects of VV119 Capsules in Chinese Healthy Volunteers","Inclusion Criteria:\n\n1. Males:aged 18 to 45 years old, males ,Body weight no less than 50.0 kg ; females :Aged 18 to 60 years old ,Body weight no less than 45.0 kg ,Body Mass Index of 19.0 to 26.0kg\u002Fm2,\n2. Medically healthy, Physical examination, vital signs examination, laboratory examination, electrocardiogram examination results were normal or abnormal without clinical significance,\n3. Males subjects who are willing to take effective contraceptive during the study and within 3 months after the study completed; females not of child-bearing potential,\n4. Subjects who are able to understand and follow study plans and instructions; Subjects who have voluntarily decided to participate in this study, and signed the informed consent form.\n\nExclusion Criteria:\n\n1. With current or past medical history diseases or dysfunction that affect the clinical trial, evaluated by the investigator, including but not limited to central nervous system, cardiovascular system, respiratory system, digestive system, urinary system, endocrine system, blood system, ophthalmology and other diseases, history of malignant tumor or other diseases that are not suitable for participating in the clinical trial;\n2. With current or previous mental disorders and brain dysfunction, or suicide risk according to the clinical judgment of the investigator, or a history of self-mutilation;\n3. With any surgical condition or condition that may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects participating in the trial, such as history of gastrointestinal surgery (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction or dysuria, gastroenteritis, gastrointestinal ulcers, history of gastrointestinal bleeding, etc.\n4. With a known history of allergy to investigating drug ingredients or similar drugs, a history of allergic diseases or allergic constitution;\n5. Positive for hepatitis B virus surface antigen (HBsAg), or syphilis antibody (Anti-TP), or hepatitis C antibody (anti-HCV), or human immunodeficiency virus antigen\u002Fantibody combined detection (HIV-Ag\u002FAb);\n6. With a history of surgery within 3 months before screening, or have not recovered from surgery, or have an expected surgical plan during the trial;\n7. With a blood donation or blood loss ≥ 400 mL within 3 months before screening, or a blood donation or blood loss ≥ 200 mL within 1 month, or a history of blood product use within 3 months before screening;\n8. Taking any prescription drugs, over-the-counter drugs, and any functional vitamins or herbal products within 2 weeks before screening;\n9. Using any drugs that inhibit or induce hepatic drug metabolizing enzymes CYP3A4, CYP3A5, CYP2D6 (such as inducers - phenobarbital, rifampicin, carbamazepine, phenytoin sodium, glucocorticoids, etc.; inhibitors - ketoconazole, itraconazole, cimetidine, clarithromycin, verapamil, erythromycin, etc.) within 4 weeks (or 5 half-lives, whichever is longer) before screening;\n10. Participating in any clinical trial and taking clinical trial drugs within 3 months before screening, or being participating in other clinical trials;\n11. Smoke test positive or smoking more than 5 cigarettes per day or average intake of coffee or tea more than 5 cups per day (200 mL\u002Fcup) within 3 months before screening, or unable to stop users during the study;\n12. With alcohol abuse within 1 year before screening, average weekly alcohol intake more than 14 standard units \\[1 unit = 360 mL beer (alcohol content 5%) or 45 mL spirits (alcohol content 40%) or 150 mL wine (alcohol content 12%)\\] or positive for alcohol breath test;\n13. With a history of drug abuse within 1 year before screening, or positive for urine drug screening;\n14. With a family history of sudden cardiac death (sudden death age less than 40 years);\n15. With a resting pulse \\\u003C 50 beats\u002Fmin or ≥ 100 beats\u002Fmin; resting systolic blood pressure \\\u003C 85 mmHg or ≥ 140 mmHg; resting diastolic blood pressure \\\u003C 50 mmHg or ≥ 90 mmHg; systolic blood pressure decreased by ≥ 20 mmHg and\u002For diastolic blood pressure decreased by ≥ 10 mmHg and\u002For accompanied by clinical symptoms within 3 minutes of standing;\n16. Abnormal in 12-lead electrocardiogram (ECG), clinically significant judged by the investigator (e.g., QTcF\\> 450 ms in men and \\> 470 ms in women);\n17. With the aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine (Cr), urea (Urea), serum prolactin levels beyond the upper limit of normal (ULN);\n18. Having special requirements for food, unable to observe a unified diet or having dysphagia;\n19. Rejecting abide by the following conditions during the trial: smoking, alcohol or caffeine-containing beverages are prohibited, and strenuous exercise is avoided;\n20. Directly related to this clinical trial;\n21. Other subjects that the investigator considers inappropriate for this trial.",{"count":157,"type":21},16,[53],"This study is a single-center, randomized, open label, 2×2 crossover design to assess the standard meal effects on PK of a single oral dose of VV119 in healthy adult subjects.",[56],"2025-12-18",{"date":163,"type":32},"2025-12-26",{"date":165,"type":32},"2025-11-28",{"date":82,"type":21},{"name":38,"class":39},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":40},"100524163","phase-1-study-of-the-safety-tolerability-pharmacokinetics-and-food-effects-of-vv119-capsules-in-chinese-healthy-volunteers-100524163","NCT06105151","Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers","A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Food Effects of a Single Oral VV119 Capsule in Healthy Chinese Volunteers","Inclusion Criteria:\n\n1. Males:aged 18 to 45 years old, males ,Body weight no less than 50.0 kg ; females :Aged 18 to 60 years old ,Body weight no less than 45.0 kg ,Body Mass Index of 19.0 to 26.0kg\u002Fm2,\n2. Medically healthy, Physical examination, vital signs examination, laboratory examination, electrocardiogram examination results were normal or abnormal without clinical significance,\n3. Males subjects who are willing to take effective contraceptive during the study and within 3 months after the study completed; females not of child-bearing potential,\n4. Subjects who are able to understand and follow study plans and instructions; Subjects who have voluntarily decided to participate in this study, and signed the informed consent form.\n\nExclusion Criteria:\n\nUnless otherwise noted, the exclusion criteria were consistent for subjects in the SAD study and FE study. The following subjects will be excluded:\n\n1. With current or past medical history diseases or dysfunction that affect the clinical trial, evaluated by the investigator, including but not limited to central nervous system, cardiovascular system, respiratory system, digestive system, urinary system, endocrine system, blood system, ophthalmology and other diseases, history of malignant tumor or other diseases that are not suitable for participating in the clinical trial;\n2. With current or previous mental disorders and brain dysfunction, or suicide risk according to the clinical judgment of the investigator, or a history of self-mutilation;\n3. With any surgical condition or condition that may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects participating in the trial, such as history of gastrointestinal surgery (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction or dysuria, gastroenteritis, gastrointestinal ulcers, history of gastrointestinal bleeding, etc.\n4. With a known history of allergy to investigating drug ingredients or similar drugs, a history of allergic diseases or allergic constitution;\n5. Positive for hepatitis B virus surface antigen (HBsAg), or syphilis antibody (Anti-TP), or hepatitis C antibody (anti-HCV), or human immunodeficiency virus antigen\u002Fantibody combined detection (HIV-Ag\u002FAb);\n6. With a history of surgery within 3 months before screening, or have not recovered from surgery, or have an expected surgical plan during the trial;\n7. With a blood donation or blood loss ≥ 400 mL within 3 months before screening, or a blood donation or blood loss ≥ 200 mL within 1 month, or a history of blood product use within 3 months before screening;\n8. Taking any prescription drugs, over-the-counter drugs, and any functional vitamins or herbal products within 2 weeks before screening;\n9. Using any drugs that inhibit or induce hepatic drug metabolizing enzymes CYP3A4, CYP3A5, CYP2D6 (such as inducers - phenobarbital, rifampicin, carbamazepine, phenytoin sodium, glucocorticoids, etc.; inhibitors - ketoconazole, itraconazole, cimetidine, clarithromycin, verapamil, erythromycin, etc.) within 4 weeks (or 5 half-lives, whichever is longer) before screening;\n10. Participating in any clinical trial and taking clinical trial drugs within 3 months before screening, or being participating in other clinical trials;\n11. Smoke test positive or smoking more than 5 cigarettes per day or average intake of coffee or tea more than 5 cups per day (200 mL\u002Fcup) within 3 months before screening, or unable to stop users during the study;\n12. With alcohol abuse within 1 year before screening, average weekly alcohol intake more than 14 standard units \\[1 unit = 360 mL beer (alcohol content 5%) or 45 mL spirits (alcohol content 40%) or 150 mL wine (alcohol content 12%)\\] or positive for alcohol breath test;\n13. With a history of drug abuse within 1 year before screening, or positive for urine drug screening;\n14. With a family history of sudden cardiac death (sudden death age less than 40 years);\n15. With a resting pulse \\\u003C 50 beats\u002Fmin or ≥ 100 beats\u002Fmin; resting systolic blood pressure \\\u003C 85 mmHg or ≥ 140 mmHg; resting diastolic blood pressure \\\u003C 50 mmHg or ≥ 90 mmHg; systolic blood pressure decreased by ≥ 20 mmHg and\u002For diastolic blood pressure decreased by ≥ 10 mmHg and\u002For accompanied by clinical symptoms within 3 minutes of standing;\n16. Abnormal in 12-lead electrocardiogram (ECG), clinically significant judged by the investigator (e.g., QTcF\\> 450 ms in men and \\> 470 ms in women);\n17. With the aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine (Cr), urea (Urea), serum prolactin levels beyond the upper limit of normal (ULN);\n18. Having special requirements for food, unable to observe a unified diet or having dysphagia;\n19. Rejecting abide by the following conditions during the trial: smoking, alcohol or caffeine-containing beverages are prohibited, and strenuous exercise is avoided;\n20. Directly related to this clinical trial;\n21. Other subjects that the investigator considers inappropriate for this trial.","60 Years",{"count":177,"type":21},82,[53],"This study will consist of 2 parts: Part Ⅰ - Single Ascending Dose (SAD) study, Part Ⅱ - Food Effect (FE) study",[96],"2025-06-05",{"date":183,"type":32},"2025-06-11",{"date":185,"type":32},"2023-10-27",{"date":187,"type":21},"2025-12",{"name":38,"class":39},""]